FDA responds to consumer demands on DEHP labelling
This article was originally published in Clinica
Executive Summary
Manufacturers of certain medical devices made of polyvinyl chloride may soon have to include a warning label or other information that the product contains the plasticiser, DEHP. The FDA disclosed that this was in prospect in a letter responding to a citizen petition filed by Health Care Without Harm (HCHW). The consumer group had requested that the FDA require that all devices containing the PVC softener carry a safety warning.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.